SCHEMBL6014056

SCHEMBL6014056

NC(=O)c1c(OCc2ccccc2)ccc(N)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PARP10 Q53GL7 1/20 0.48
HTT P42858 1/20 0.45
PARP1 P09874 1/20 0.44
CA9 Q16790 1/20 0.44
FOLH1 Q04609 2/20 0.44
SIRT2 Q8IXJ6 1/20 0.42
SMPD1 P17405 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
LTA4H P09960 1/20 0.42
MAPK14 Q16539 1/20 0.42
RXRA P19793 1/20 0.41
BRD4 O60885 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL891074 0.99 MAPT (0.47) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL14110232 0.87 MAPT (0.57) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL11464594 0.82 FOLH1 (0.52) MAPTTDP1L3MBTL1PARP10HTT
SCHEMBL5743109 0.81 FOLH1 (0.57) MAPTTDP1L3MBTL1PARP10HTT
SCHEMBL6014059 0.80 CTSV (0.48) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL6358665 0.79 MAOB (0.56) MAPTTDP1L3MBTL1PARP10HTT
SCHEMBL4346081 0.77 MAPT (0.57) MAPTSMN1; SMN2L3MBTL1PARP10HTT
SCHEMBL14070590 0.76 MAPT (0.43) MAPTCYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL15709508 0.75 RXRA (0.54) MAPTSMN1; SMN2PARP10HTTSMPD1
SCHEMBL23629037 0.75 PARP10 (0.60) SMN1; SMN2PARP10PARP1SMPD1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029901-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH Pradama, Inc. 2013-01-31 US disclosed
US-20130029901-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH Pradama, Inc. 2013-01-31 US disclosed
US-20120083440-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH Pradama, Inc. 2012-04-05 US disclosed
US-20120083440-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH Pradama, Inc. 2012-04-05 US disclosed
US-8071575-B2 Methods and compounds for the targeted delivery of agents to bone for interaction therewith UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2011-12-06 US disclosed
US-8071575-B2 Methods and compounds for the targeted delivery of agents to bone for interaction therewith UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2011-12-06 US disclosed
US-20090118164-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2009-05-07 US disclosed
US-20090118164-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2009-05-07 US disclosed
WO-2008109780-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC (US) 2008-09-12 WO disclosed
US-20080221070-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2008-09-11 US disclosed
US-20080221070-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2008-09-11 US disclosed
WO-2008103951-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC (US) 2008-08-28 WO disclosed
US-20070161710-A1 BONE TARGETING COMPOUNDS FOR DELIVERING AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2007-07-12 US disclosed
US-20070161710-A1 BONE TARGETING COMPOUNDS FOR DELIVERING AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2007-07-12 US disclosed
US-7196220-B2 Bone targeting compounds for delivering agents to the bone for interaction therewith UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2007-03-27 US disclosed
US-7196220-B2 Bone targeting compounds for delivering agents to the bone for interaction therewith UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2007-03-27 US disclosed
EP-1697302-A1 COMPOUNDS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE INJURY AND METABOLIC DISORDERS University of Louisville Research Foundation (US) 2006-09-06 EP disclosed
WO-2005066114-A1 COMPOUNDS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE INJURY AND METABOLIC DISORDERS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2005-07-21 WO disclosed
US-20050143366-A1 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. 2005-06-30 US disclosed
WO-2000066613-A1 BONE TARGETING AGENTS FOR OSTEOPOROSIS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221070-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH SHBG, ESRRA, ESRRG MAPT 4413/4885CYP2C9 3336/4885CYP2C19 3456/4885
US-20050143366-A1 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders SOST, BMP2, BMP4 MAPT 3800/4885CYP2C9 2921/4885CYP2C19 2541/4885
US-20120083440-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH BMP2, SOST, BMP4 MAPT 4451/4885CYP2C9 4717/4885CYP2C19 4805/4885
US-20130029901-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH BMP2, SOST, BMP4 MAPT 4451/4885CYP2C9 4717/4885CYP2C19 4805/4885
US-20070161710-A1 BONE TARGETING COMPOUNDS FOR DELIVERING AGENTS TO BONE FOR INTERACTION THEREWITH SOST, BMP2, BMP6 MAPT 4393/4885CYP2C9 4533/4885CYP2C19 4413/4885
US-20090118164-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH BMP2, SOST, BMP4 MAPT 4451/4885CYP2C9 4717/4885CYP2C19 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.